Natalizumab (AN100226, BG00002) is a humanized monoclonal IgG4 antibody inhibitor that selectively targets alpha4 integrin (CD49d). It blocks the interaction of integrins such as alpha4beta1 (VLA-4) with vascular cell adhesion molecule VCAM-1, intercellular adhesion molecule ICAM-1, and fibronectin by competitively binding to the alpha4 subunit. Natalizumab inhibits the adhesion, retention, and transendothelial migration of immune cells (such as CD4+ T cells), reducing the infiltration of inflammatory cells into the central nervous system or lesion sites, thus exerting anti-inflammatory and immunomodulatory activity. Natalizumab is used in the study of relapsing-remitting multiple sclerosis (RRMS) and also has applications in the study of autoimmune or inflammation-related diseases such as Crohns disease, B-cell lymphoma, and non-infectious uveitis. Natalizumab can also prevent lymphocytes from entering the central nervous system, thereby preventing acute demyelinating relapses[1][2][3][4][5].
Molecular Weight:
(146.19 kDa)
Purity:
99.10
CAS Number:
[189261-10-7]
Target:
Integrin
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted
